Bedaquiline or delamanid improves the quality of life among patients with drug-resistant tuberculosis.
作者信息
Putra Oki N, Purnamasari Telly
机构信息
Department of Clinical and Community Pharmacy, Faculty of Pharmacy, Hang Tuah University, Surabaya Indonesia, Indonesia.
Pre-Clinical and Clinical Research Centre, BRIN, Cibinong, Indonesia.
出版信息
J Family Med Prim Care. 2025 Jul;14(7):3065-3066. doi: 10.4103/jfmpc.jfmpc_1912_24. Epub 2025 Jul 21.
Abstract
摘要
相似文献
1
Bedaquiline or delamanid improves the quality of life among patients with drug-resistant tuberculosis.贝达喹啉或地拉曼尼可改善耐多药结核病患者的生活质量。
J Family Med Prim Care. 2025 Jul;14(7):3065-3066. doi: 10.4103/jfmpc.jfmpc_1912_24. Epub 2025 Jul 21.
2
Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review.贝达喹啉和德拉马尼单用方案治疗耐药结核病的良好结局：一项系统评价。
Int J Mycobacteriol. 2023 Jan-Mar;12(1):1-9. doi: 10.4103/ijmy.ijmy_217_22.
3
Efficacy and safety of bedaquiline and delamanid in the treatment of drug-resistant tuberculosis in adults: A systematic review and meta-analysis.贝达喹啉和德拉马尼治疗成人耐多药结核病的疗效和安全性：系统评价和荟萃分析。
Indian J Tuberc. 2024 Jan;71(1):79-88. doi: 10.1016/j.ijtb.2023.05.005. Epub 2023 May 12.
4
Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.德拉马尼与贝达喹啉联合用于治疗耐多药和广泛耐药结核病：一项系统评价
Int J Mol Sci. 2017 Feb 7;18(2):341. doi: 10.3390/ijms18020341.
5
Model-Informed Once-Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis.贝达喹啉和地拉曼啶用于儿童、青少年及成人结核病患者的模型指导每日一次给药策略
Clin Pharmacol Ther. 2025 May;117(5):1292-1302. doi: 10.1002/cpt.3536. Epub 2024 Dec 28.
6
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.在德国，将新型或第5组干预措施添加到背景治疗方案中用于治疗耐多药结核病的成本效益。
BMC Health Serv Res. 2017 Mar 8;17(1):182. doi: 10.1186/s12913-017-2118-2.
7
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.贝达喹啉、德拉马尼或两者联合治疗利福平耐药结核病患者的 QT 影响：一项 2 期、开放标签、随机、对照试验。
Lancet Infect Dis. 2021 Jul;21(7):975-983. doi: 10.1016/S1473-3099(20)30770-2. Epub 2021 Feb 12.
8
Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid.贝达喹啉或德拉马尼治疗耐多药结核病的结果。
Clin Infect Dis. 2021 Oct 20;73(8):1362-1369. doi: 10.1093/cid/ciab304.
9
Clinical outcomes of multidrug-resistant tracheobronchial tuberculosis receiving anti-tuberculosis regimens containing bedaquiline or delamanid.含贝达喹啉或德拉马尼方案治疗耐多药支气管结核的临床结局。
Sci Rep. 2024 Jul 29;14(1):17347. doi: 10.1038/s41598-024-68550-0.
10
Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China.中国耐贝达喹啉和德拉马尼的结核分枝杆菌流行率。
J Glob Antimicrob Resist. 2021 Sep;26:241-248. doi: 10.1016/j.jgar.2021.06.007. Epub 2021 Jun 30.
本文引用的文献
1
Evaluation of health-related quality of life and adherence among pre-extensively drug-resistant tuberculosis patients receiving either Bedaquiline or Delamanid regimen at a teaching hospital in Eastern India.在印度东部一家教学医院，对接受贝达喹啉或德拉马尼治疗方案的广泛耐药前结核病患者的健康相关生活质量和依从性进行评估。
J Family Med Prim Care. 2024 Oct;13(10):4684-4692. doi: 10.4103/jfmpc.jfmpc_572_24. Epub 2024 Oct 18.
2
Health-related quality of life of multidrug-resistant tuberculosis patients: A study of eastern Uttar Pradesh, India.耐多药结核病患者的健康相关生活质量：印度北方邦东部的一项研究。
Indian J Tuberc. 2022 Jul;69(3):347-353. doi: 10.1016/j.ijtb.2021.06.002. Epub 2021 Jun 15.
3
Health-Related Quality of Life in Tuberculosis Patients in Eritrea: Comparison Among Drug-Susceptible and Rifampicin/Multidrug-Resistant Tuberculosis Patients.厄立特里亚结核病患者的健康相关生活质量：药物敏感型与利福平/耐多药结核病患者的比较
Patient Relat Outcome Meas. 2021 Jun 29;12:205-212. doi: 10.2147/PROM.S316337. eCollection 2021.
Zotero 插件